No tissue sections of primary breast carcinomas from patients with HER2+ or triple-negative breast cancer (TNBC) could be included in the study since these patients had already received neoadjuvant treatment prior to the collection of the primary tumor samples. Here, ERBB2 is linked to triple-negative breast carcinoma.